Skip to main content
Clinical Trials/NCT01175161
NCT01175161CompletedNot Applicable

A Pilot Study Of A Randomized Trial Comparing Two Different Time Frames For Copper T380A Intrauterine Contraception Insertion; Immediately Postpartum Compared To 4-6 Weeks Postpartum In Lilongwe, Malawi

University of North Carolina, Chapel Hill1 site in 1 country115 target enrollmentStarted: October 1, 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
115
Locations
1
Primary Endpoint
Time

Study Overview

Brief Summary

The purpose of this non-blinded randomized clinical trial is to pilot the design of a randomized clinical trial to be conducted in Malawi to investigate immediate postpartum insertion of the Copper T380 intrauterine contraceptive device (CuT380A-IUCD) compared to placement at the 6-week postpartum visit.

The investigators hypothesize that it will be feasible to enroll 140 women into this study, and that women will find the 10 minute to 48 hour time frame for IUCD placement acceptable.

Detailed Description

Women will be enrolled into the study during prenatal care. After delivery, if they meet secondary eligibility criteria, they will be randomized to receive the IUD immediately postpartum or at the 6-week postpartum visit. Women will be followed at 4, 8, and 12 weeks after IUD insertion, and be assessed at those time points for satisfaction with the method and IUD expulsion.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Primary Inclusion Criteria:
  • •Ages 18-45 attending prenatal care
  • •Greater than 34 weeks estimated gestational age
  • •Desire to use the CuT380A-IUCD for contraception postpartum
  • •Plan to stay in the area for at least 5 months postpartum
  • •If HIV+ the women must be WHO Clinical Stage 1 or 2, or known to be clinically well on antiretroviral therapy as documented in their health passport
  • •No prior cesarean delivery
  • •No treatment for pelvic inflammatory disease within 3 months prior to pregnancy
  • •No known uterine anomalies
  • •No known pelvic tuberculosis
  • •No known genital tract cancer
  • •No known allergy to copper
  • •No known history of ectopic pregnancy within 3 months prior to pregnancy.
  • •No evidence of clinical anemia as assessed by a clinician at enrollment
  • •Any other condition a clinician feels should preclude the woman from receiving the IUCD 10-minutes to 48 hours after delivery
  • •Secondary Eligibility Criteria
  • •Vaginal delivery within the last 48 hours
  • •No postpartum hemorrhage documented by the delivering clinician
  • •Not known to have ruptured membranes for greater than 24 hours prior to delivery
  • •No infection diagnosed by a clinician
  • •No fever of greater than 38° during labour or delivery
  • •Any other condition which a clinician feels precludes the woman from receiving the IUCD 10 minutes to 48 hours after delivery.

Exclusion Criteria

  • •prior cesarean section
  • •fever during labor and delivery
  • •AIDS, not well on antiretroviral therapy
  • •genital tuberculosis
  • •known uterine abnormalities or genital tract cancer
  • •history of ectopic pregnancy within 3 months of current pregnancy

Arms & Interventions

Immediate postpartum IUD insertion

Experimental

Women assigned to have the IUD placed 10 minutes to 48 hours postpartum

Intervention: Copper T380A Intrauterine Device (Device)

6 week postpartum IUD insertion

Experimental

Women who receive the IUD at the traditional time frame.

Intervention: Copper T380A Intrauterine Device (Device)

Outcomes

Primary Outcomes

Time

Time Frame: 6 months

Estimate the time required to enroll 140 women into this study

Secondary Outcomes

  • Expulsion rates(6 months)
  • Satisfaction(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Amy Bryant

Fellow

University of North Carolina, Chapel Hill

Study Sites (1)

Loading locations...

Similar Trials